During the last session, Apogee Therapeutics Inc (NASDAQ:APGE)’s traded shares were 1.06 million, with the beta value of the company hitting 2.44. At the end of the trading day, the stock’s price was $35.44, reflecting an intraday gain of 12.76% or $4.01. The 52-week high for the APGE share is $72.29, that puts it down -103.98 from that peak though still a striking 17.89% gain since the share price plummeted to a 52-week low of $29.10. The company’s market capitalization is $2.11B, and the average trade volume was 541.45K shares over the past three months.

Apogee Therapeutics Inc (NASDAQ:APGE) trade information

Apogee Therapeutics Inc (APGE) registered a 12.76% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 12.76% in intraday trading to $35.44, hitting a weekly high. The stock’s 5-day price performance is 16.08%, and it has moved by -12.45% in 30 days. Based on these gigs, the overall price performance for the year is -15.09%.

The consensus price target of analysts on Wall Street is $95, which implies an increase of 62.69% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $95 and $95 respectively. As a result, APGE is trading at a discount of -168.06% off the target high and -168.06% off the low.

While earnings are projected to return -47.74% in 2025, the next five years will return -25.65% per annum.

APGE Dividends

Apogee Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

The next largest institutional holding, with 2.71 million shares, is of RTW INVESTMENTS, LP’s that is approximately 4.7989% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $106.72 million.